Former Affiliate Files Intent to Sell $11.4M in Shares via Option Exercise
AUPH has more than doubled off its 52-week low of $7.285 on elevated volume (1.9× avg).
Summary
A former affiliate of Aurinia Pharmaceuticals intends to sell $11.4 million in shares through a cashless option exercise, a notable transaction for a former executive.
Key Events · Ownership and Investor Activity · AUPH
-
Intent to Sell Shares
Matthew Maxwell Donley, a former affiliate, filed a Form 144 to sell 717,688 common shares.
-
Significant Transaction Value
The proposed sale has an approximate market value of $11,368,177.92.
-
Cashless Option Exercise
The sale is described as a cashless exercise of options and subsequent sale of the underlying shares, commencing on May 11, 2026.
Analysis · AUPH · Life Sciences
A former affiliate of Aurinia Pharmaceuticals, Matthew Maxwell Donley, has filed a Form 144 indicating an intent to sell approximately $11.4 million worth of common shares. This transaction is described as a cashless exercise of options and subsequent sale of the underlying shares. While the sale is significant, representing over 0.5% of the company's market capitalization, it stems from a former executive's option exercise rather than a current insider's direct market sale, which typically carries less of a negative signal regarding current company prospects.
At the time of this filing, AUPH was trading at $15.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $7.29 to $16.88. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.